Introducing the new Regenerative Medicine aims and scope

Written by Regenerative Medicine

In light of the 10-year anniversary of the award-winning journal Regenerative Medicine, Commissioning Editor Elena Conroy and Senior Editor Chris Mason are delight to announce an update to the journal’s aims and scope.

The field of regenerative medicine has undergone significant change in the last 10 years. We have grown mini organs, edited the genome of cells with specificity, grown organs from scaffolds, begun 3D printing tissues and much more. In light of this advancement, the Editors of Regenerative Medicine and Senior Editor Chris Mason have updated the scope to include the full breadth of modern regenerative medicine:

medicine replaces or regenerates human cells, tissue or organs, to
restore or establish normal function*. Since 2006, Regenerative Medicine has
been at the forefront of publishing the very best papers and reviews
covering the entire regenerative medicine sector. The journal focuses on
the entire spectrum of approaches to regenerative medicine, including
small molecule drugs, biologics, biomaterials and tissue engineering,
and cell and gene therapies — it’s all about regeneration and not a
specific platform technology. The journal’s scope encompasses all
aspects of the sector ranging from discovery research, through to
clinical development, through to commercialization. Regenerative Medicine
uniquely supports this important area of biomedical science and
healthcare by providing a peer-reviewed journal totally committed to
publishing the very best regenerative medicine research, clinical
translation and commercialization.

Regenerative Medicine
provides a specialist forum to address the important challenges and
advances in regenerative medicine, delivering this essential information
in concise, clear and attractive article formats — vital to a rapidly
growing, multidisciplinary and increasingly time-constrained community.

Regenerative Medicine
exclusively supports all avenues that lead to the replacement or
regeneration of human cells, tissue or organs, to restore or establish
normal function. The sector is complex, rapidly evolving and
multidisciplinary in nature, however, Regenerative Medicine
is highly dynamic and has always embraced the progress made by the
field and moved accordingly to support the critical issues including:

  • Bench-to-bedside translation
  • Tissue engineering and organ replacement
  • Regenerative pharmacology
  • Cell and gene therapy
  • Regenerative nanotechnology
  • Manufacturing and cost of goods
  • Regulatory and reimbursement
  • Ethical and legal perspectives
  • Business models and commercialization
  • Government policy

substantial developments in our knowledge and understanding of
regeneration, the field is still in its infancy. However, progress is
accelerating. The next few decades will see the discovery and
development of transformative therapies for patients, and in some cases,
even cures. Regenerative Medicine will
continue to provide a critical overview of these advances as they
progress, undergo clinical trials, and eventually become mainstream

*Mason C. and Dunnill P. (2008) A brief definition of regenerative medicine. Regenerative Medicine. 3(1), 1-5.

The new scope will be officially presented at the World Stem Cell Summit it Atlanta this week. If you have any questions or are interested in submitting, please contact Commissioning Editor Elena Conroy ([email protected]) and if you’re attending the conference, please come by to booth #211.